<div>
  <p>
  </p>
  <ul>
    <li>
      <p>
        Compass Pathways, a UK-based psychedelic company, and Mindful Health, a mental healthcare provider, have entered a research collaboration to explore a scalable delivery model for COMP360 psilocybin treatment for treatment-resistant depression, currently under FDA review.
      </p>
    </li>
    <li>
      <p>
        The partnership will involve both parties sharing information on the delivery model of the COMP360 program. The research will focus on patient journeys, current challenges, and solutions. Mindful Health Solutions will undergo training in Compass' support model, researching therapist training needs. Furthermore, both will explore treatment room setups, site activation, and coding/reimbursement for psychedelic treatments.
      </p>
    </li>
    <li>
      <p>
        <b>Analyst QuickTake</b>
        : This marks Compass Pathway&rsquo;s fourth collaboration this year in support of its product development initiatives. Previous partnerships include 1) Journey Clinical to develop a deployment and training model for COMP360 (
        <a href="https://sp-edge.com/updates/28939">
          April 2024
        </a>
        ), 2) Hackensack Meridian Health to support research efforts using psilocybin in mental health treatments (
        <a href="https://sp-edge.com/updates/25618">
          January 2024
        </a>
        ), and 3) Greenbrook TMS to explore delivery models for COMP360 (
        <a href="https://sp-edge.com/updates/25237">
          January 2024
        </a>
        ). 
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://compasspathways.com/compass-pathways-establishes-research-collaboration-with-mindful-health-solutions-to-inform-the-development-of-a-scalable-and-cost-effective-delivery-model-for-investigational-comp360-psilocybin-treat/">
      Press release
    </a>
  </p>
</div>


Psychedelic Medicine

ANALYST_QUICK_TAKE

PROMINENT_CATEGORY

<div>
 
 <p>Compass Pathways and Mindful Health Solutions have established a research collaboration. The partnership aims to investigate a scalable delivery model for the COMP360 psilocybin treatment for treatment-resistant depression, a subject currently under the consideration of the FDA. </p>
 <p>In this collaboration, both parties will share insights regarding the delivery model of the COMP360 program. The primary focus of this research will be on examining patient journeys, identifying existing challenges, and developing solutions. Mindful Health Solutions will be trained in Compass' support model and will conduct research on the requirements for therapist training. They will additionally evaluate treatment room configurations, site activation, and coding/reimbursement procedures for psychedelic treatments. </p>
 
</div> <p><b>Analyst QuickTake</b> :<br>
 This marks Compass Pathway’s fourth collaboration this year in support of its product development initiatives. Previous partnerships include 1) Journey Clinical to develop a deployment and training model for COMP360 ( <a href="https:<br>
//sp-edge.com/updates/28939"> April 2024 </a> ), 2) Hackensack Meridian Health to support research efforts using psilocybin in mental health treatments ( <a href="https:<br>
//sp-edge.com/updates/25618"> January 2024 </a> ), and 3) Greenbrook TMS to explore delivery models for COMP360 ( <a href="https:<br>
//sp-edge.com/updates/25237"> January 2024 </a> ).</p>

Compass Pathways and Mindful Health Solutions collaborate to research on scalable psilocybin treatment model

<div>
 <p>A UK-based psychedelic company, Compass Pathways, and Journey Clinical, a psychotherapy platform, have formed a research collaboration. Their aim is to investigate the deployment and health provider training for COMP360 psilocybin treatment for treatment-resistant depression (TRD), which is currently being reviewed by the FDA.</p>
 <p>The collaboration will involve sharing information about the delivery model of the COMP360 program. If the FDA approves COMP360 for TRD, the partners will further analyze patient experiences, reimbursement processes, innovative care pathways. They will also examine therapist training and treatment settings.</p>
 
</div> <p><b>Analyst QuickTake:<br>
 </b> As Compass Pathways nears FDA approval for its psilocybin program, it is actively partnering with others to support its product development initiatives. In January 2024, it partnered with <a href="https:<br>
//sp-edge.com/updates/25618"> Hackensack Meridian Health </a> to support research efforts using psilocybin in mental health treatments. Also, during the same month, it partnered with <a href="https:<br>
//sp-edge.com/updates/25237"> Greenbrook TMS </a> to explore delivery models for the COMP360 program.</p>

Compass Pathways and Journey Clinical collaborate to develop deployment and training model for COMP360 psilocybin treatment

<div>
 
 <p>Compass Pathways, a UK psychedelic company, is collaborating with Hackensack Meridian Health, a New Jersey healthcare network, to conduct research on psilocybin use in mental health treatments. The venture will use Hackensack Meridian Health's expertise to enhance the application and delivery model of COMP360, Compass's investigational psilocybin treatment. Compass intents to apply psilocybin in treating not just PTSD, but also treatment-resistant depression and anorexia nervosa. Research findings are anticipated between summer 2024 and mid-2025.</p>
 
</div>

Compass Pathways partners with Hackensack Meridian Health partner for research on psilocybin treatment

<div>
 
<p>UK psychedelic company, Compass Pathways, has entered a three-year research agreement with Greenbrook TMS, a provider of mental health therapies. They will research delivery models for the COMP360 psilocybin treatment under FDA review. The aim is to find scalable and cost-effective methods for delivering COMP360 across healthcare systems, pending FDA approval. The initial phase will involve delivering COMP360 at treatment centers across the US, including Greenbrook's centers. The target patients are those with treatment-resistant depression and other mental health conditions.</p>
 
</div>

All Updates

Compass Pathways and Mindful Health Solutions collaborate to research on scalable psilocybin treatment model

Compass Pathways and Journey Clinical collaborate to develop deployment and training model for COMP360 psilocybin treatment

Compass Pathways partners with Hackensack Meridian Health partner for research on psilocybin treatment

Compass Pathways and Greenbrook TMS collaborate to explore delivery models for COMP360 treatment

COMPASS Pathways announces private placement up to USD 285 million

Compass Pathways Q2 2023 results beat EPS analyst expectations

Compass Pathway receives USD 50 million via term loan facility

Numinus to commence clinical study of COMP360 psilocybin therapy for treatment-resistant depression

Compass Pathways Q1 2023 results beat EPS analyst expectations

Compass Pathways Q4 and full-year 2022 results miss revenue and EPS analyst expectations